Search details
1.
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
Ann Surg Oncol
; 30(2): 1099-1109, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36305992
2.
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
BJU Int
; 127(4): 435-444, 2021 04.
Article
in English
| MEDLINE | ID: mdl-32969563
3.
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Lancet Oncol
; 21(8): 1099-1109, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32645282
4.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Article
in English
| MEDLINE | ID: mdl-27939400
5.
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
BJU Int
; 118(4): 590-7, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-26780387
6.
Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
Cureus
; 16(3): e55729, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38586683
7.
Impact of neoadjuvant relugolix on patient-reported sexual function and bother.
Front Oncol
; 14: 1377103, 2024.
Article
in English
| MEDLINE | ID: mdl-38665954
8.
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
J Clin Invest
; 2024 Apr 23.
Article
in English
| MEDLINE | ID: mdl-38652565
9.
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Front Oncol
; 13: 1289249, 2023.
Article
in English
| MEDLINE | ID: mdl-37916156
10.
Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.
Future Oncol
; 7(4): 551-8, 2011 Apr.
Article
in English
| MEDLINE | ID: mdl-21463143
11.
Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Urol Oncol
; 39(6): 367.e7-367.e17, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33736976
12.
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kß Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 27(19): 5248-5257, 2021 10 01.
Article
in English
| MEDLINE | ID: mdl-34281912
13.
Update on castrate-resistant prostate cancer: 2010.
Curr Opin Oncol
; 22(3): 263-7, 2010 May.
Article
in English
| MEDLINE | ID: mdl-20177381
14.
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
BJU Int
; 106(7): 966-73, 2010 Oct.
Article
in English
| MEDLINE | ID: mdl-20840318
15.
Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
J Med Econ
; 23(1): 54-63, 2020 Jan.
Article
in English
| MEDLINE | ID: mdl-31589086
16.
An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Mol Cancer Ther
; 19(6): 1373-1382, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32220973
17.
Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.
Front Oncol
; 10: 606260, 2020.
Article
in English
| MEDLINE | ID: mdl-33537236
18.
Emerging therapies in castrate-resistant prostate cancer.
Curr Opin Oncol
; 21(3): 260-5, 2009 May.
Article
in English
| MEDLINE | ID: mdl-19363343
19.
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Clin Genitourin Cancer
; 6(2): 110-6, 2008 Sep.
Article
in English
| MEDLINE | ID: mdl-18824434
20.
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
J Clin Oncol
; 36(15): 1498-1504, 2018 05 20.
Article
in English
| MEDLINE | ID: mdl-29624463